CME/CE Accreditation Information Return to Previous

Oncology Innovations: Improving Management of Locally Advanced and Metastatic CSCC and MBC

Jointly provided by Postgraduate Institute for Medicine and DKBMed.

This activity is supported by an independent medical education grant from Merck & Co. Inc. and Regeneron Pharmaceuticals, Inc, and Sanofi Genzyme.

Release date: 10/21/22
Expiration date: 10/21/23

Estimated time to complete activity: 3.0 hours

If you have questions regarding the certification of this activity, please contact PIM via email at

Oncology Innovations: Metastatic Non-Small Cell Lung Cancer (NSCLC) updates learners on the latest guideline recommendations for biomarker screening and staging of NSCLC. The program will enable learners to select appropriate targeted treatment pathways based on the tumor profile, while incorporating the latest scientific advances applicable to a broad range of patients with PD-L1–positive NSCLC. 
By participating in the program, you will be better able to identify actionable use of checkpoint inhibitors, develop chemotherapy-free strategies, and evaluate current and emerging first-line treatments for patients newly diagnosed with NSCLC.

These modules reference guidelines that are updated regularly. Therefore, the information in the modules may not be the most current at the time you view the information. The group leader will discuss relevant updates during your course.

Target Audience

This activity is intended for oncologists, pulmonologists, and others engaged in the care of patients with non-small cell lung cancer.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Identify actionable use of checkpoint inhibitors based on results of molecular testing for patients with newly diagnosed NSCLC. 
  • Develop chemotherapy-free strategies using checkpoint inhibitors for patients with newly diagnosed NSCLC, TPS > 50%, and no targetable driver mutations.
  • Evaluate current and emerging first-line treatment using checkpoint inhibitors for patients with newly diagnosed NSCLC, PTS > 1% and < 50%, and no targetable driver mutations.


Justin Gainor, MD
Director, Center for Thoracic Cancers
Director of Target Immunotherapy
Associate Professor of Medicine at Harvard Medical School
Boston, MA

Raffaele Califano, MD
Honorary Senior Lecturer, Division of Cancer Sciences, The University of Manchester
Consultant in Medical Oncology, The Christie NHS Foundation Trust
Manchester, UK

Mark Awad, MD, PhD
Director of Clinical Research, Advanced Fellowship Program Director, Thoracic Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, MA

Todd Bauer, MD
Tennessee Oncology and Sarah Cannon Research Institute 
Nashville, TN 

Mary Jo Fidler, MD
Professor of Medicine
Section Chief of Medical Oncology
Rush University Medical Center
Division of Hematology, Oncology, and Cell Therapy

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Justin Gainor, MD
Grant/Research Support: Novartis, Genentech/Roche, Ariad/Takeda, Bristol-Myers Squibb, Tesaro, Moderna, Blueprint, Jounce, Array Biopharma, Merck & Co., Inc. Adaptimmune, Novartis, Alexo
Consultant/Advisory Board: Bristol-Myers Squibb, Genentech, Ariad/Takeda, Loxo/Lilly, Blueprint, Oncorus, Regeneron Pharmaceuticals, Inc, Gilead Sciences, Inc., Moderna, AstraZeneca, Pfizer, Novartis, Merck & Co., Inc., and GlydeBio

Raffaele Califano, MD
Grant/Research Support: Roche, AstraZeneca, Pfizer, Clovis, Lilly Oncology, MSD, Bristol-Myers Squibb, AbbVie, Takeda, and Novartis
Speakers Bureau/Honoraria for non-CME: AstraZeneca, Boehringer Ingelheim, Lilly Oncology, Roche, Pfizer, MSD, Bristol-Myers Squibb, Bayer, Sanofi, Amgen, and Novartis
Stocks: The Christie Private Care

Todd Bauer, MD
Speakers Bureau/Honoraria for non-CME: Eli Lilly and Company and Dava Pharmaceuticals Inc.
Consultant/Advisory Board: Pfizer, Bayer, BerGenBio

Mary Jo Fidler, MD
Grant/Research Support: Biodesix and Pfizer
Speakers Bureau/Honoraria for non-CME: Jazz Pharmaceuticals and BeiGene
Consultant/Advisory Board: Genentech, Janssen, Jazz Pharmaceuticals, Biodesix, Sanofi, Daiichi, and Gilead Sciences, Inc.

The PIM planners and others have nothing to disclose. The DKBmed planners and others have nothing to disclose.

Method of Participation and Request for Credit

To claim the maximum amount of credit available (3.0 AMA PRA Category 1 Credits™) you must complete the following, including all pre and final assessments:

Baseline Assessment - 0.25 credits
Self-Study Module 1 – 0.50 credits
Self-Study Module 2 - 0.50 credits
Final Assessment - 0.25 credits
Live Group Session 1 - 0.5 credits
Live Group Session 2 - 0.5 credits
Group Task - 0.5 credits

Total credit amount - 3.0 credit hours

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBMed. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.0 contact hours.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.